Riverbridge Partners LLC Has $20.28 Million Stock Position in Certara, Inc. (NASDAQ:CERT)

Riverbridge Partners LLC cut its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 5.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,048,519 shares of the company's stock after selling 116,228 shares during the quarter. Riverbridge Partners LLC owned about 1.27% of Certara worth $20,280,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. ArrowMark Colorado Holdings LLC increased its holdings in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Certara by 864.0% during the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after acquiring an additional 3,387,590 shares during the last quarter. Mackenzie Financial Corp bought a new position in Certara during the fourth quarter valued at $17,852,000. Brown Brothers Harriman & Co. boosted its holdings in shares of Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after acquiring an additional 1,487,998 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after acquiring an additional 1,253,385 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CERT. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target on the stock. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. KeyCorp lifted their target price on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Finally, William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Stock Performance

Shares of CERT stock opened at $10.57 on Friday. The firm has a market capitalization of $1.71 billion, a P/E ratio of -528.50 and a beta of 1.44. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.93. The firm's fifty day simple moving average is $12.29 and its 200 day simple moving average is $11.86.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. During the same period last year, the firm earned $0.10 earnings per share. The business's revenue for the quarter was up 9.7% on a year-over-year basis. As a group, sell-side analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.